ArticleArchives of dermatological research2025
Efficacy of intralesional acyclovir versus quadrivalent human papillomavirus vaccine for treatment of recalcitrant cutaneous warts: a clinical trial.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cutaneous papillomaviruses infection rewires fatty-acid metabolism.Frontiers in cellular and infection microbiology · 2026Article
- Intralesional Immunotherapy for Non-Genital Viral Warts: A Review of Current Evidence and Future Perspectives.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Warts are the cutaneous manifestations of human papilloma virus infection. Immunotherapy with human papillomavirus (HPV) vaccines has been tried with promising outcomes. Acyclovir is an antiviral with established efficacy against DNA viruses, could become a possible revolutionary therapeutic option for warts. This study aims to assess the efficacy and safety of intralesional acyclovir versus quadrivalent human papilloma virus vaccine in treatment of recalcitrant cutaneous warts. A total of 60 patients with recalcitrant warts were assigned into 3 groups: group I, 20 patients received Intralesional injection of acyclovir, group II, 20 patient received intralesional quadrivalent HPV vaccine, and group III, 20 patients received intralesional injection of normal saline. The patients were followed up monthly for 3 months after the last injection to detect any recurrence. Complete clearance was observed in 8 patients (40%) in group I, 16 patients (80%) in group II and no response in group III. The most common side effects were pain (100%) among all groups, hemorrhagic eschars in group I(100%), edema in group II(30%) while the least was flu like symptoms (5%) in group II. both intralesional quadrivalent HPV vaccine and intralesional acyclovir seem to be promising, well-tolerated therapeutic options for the treatment of warts, with statistically significant superiority of the quadrivalent vaccine over acyclovir.
Indexed as
Identifiers
40056255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.